C the Signs

What happens during the consultation?

The vendor says the tool checks "over 1,000 validated signs, symptoms, and risk factors", reads structured and unstructured record data and writes coded entries back with no extra clicks. It states FHIR and HL7 compliance. Recommendations follow "national and local guidelines", and NICE is not named. A second mode, in the vendor's words, scans data across entire populations for at-risk patients.

The homepage claims detection across more than 100 cancer types, 99% sensitivity, a referral decision in under 60 seconds and time to diagnosis cut in half. The vendor does not say how the 99% was measured. It also describes a data collaboration with Mayo Clinic.

Who runs C the Signs?

C the Signs Limited is Companies House number 10683539, incorporated on March 22, 2017, with its registered office at Gridiron Building, 1 Pancras Square, London. Dr Bea Bakshi is co-founder and CEO and Dr Miles Payling is co-founder and Chief Scientific Officer. The story page says the company started in the NHS. Vendor pages give no funding history.

Among the compliance claims on the vendor's page are UKCA Class I medical device status, the NHS Data Security and Protection Toolkit, a DTAC pass and HIPAA and HITECH compliance for the US. No FDA clearance is claimed.

What do the published results show?

The evidence is the vendor's research page, which lists 17 items, most with Payling, Dadhania and Bakshi among the authors. A 2025 JNCCN supplement on pancreatic cancer drew on more than 895,000 Mayo Clinic records and reported 23% of cases identified up to five years earlier, at specificity of 72%. Sensitivity in the conference abstracts runs from 77% for breast cancer (AACR 2025, negative predictive value 99%) to 94% for colorectal (ASCO GI 2025), with lung at 92% and prostate at 83% (ASCO 2025). An ESMO 2025 abstract from Somerset reports a 36% stage shift, and a 2025 retrospective ovarian cancer analysis (ScienceDirect) reports early diagnoses of about 22% to 33%.

Several of these are retrospective analyses of cancers already diagnosed, so they measure how much earlier a case could have been flagged. A health economic assessment reporting an 808% return and GBP 1.5 million in savings is a model.

How is it bought?

NHS bodies commission it. The what-we-do page shows no pricing, and the economic abstract models the return without stating a price.

The verdict

A commissioner reading these results is relying on retrospective, vendor-authored analyses and a single Somerset abstract for stage shift. Within England, the listed integrations with EMIS, SystmOne and Vision are the practical draw. A practice on another system has no stated connector.